Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (1107)	8/2/1998 12:19:00 PM
From: Zvi Steinberg	Read Replies (2) \| Respond to of 1491

Ariella, Thanks for the analysis. Wish I had some free cash to load on more shares, but am happy with my current position and its average price. Meanwhile, from today's Globes, some harsh words regarding PARS PR: "A share like Pharmos, for example, will not emerge from the grave it is in at present unless it urgently sends Wall Street a series of clear and attractive messages. It isn't enough to set up an Internet site and say that's it, we've done it. It's also necessary to hire the services of professional people such as Deb Triant (Check Point), who know how to say all the right things in all the right places. It costs money, but perhaps the time has come to cut spending on a lab rat. Or maybe two." While I question the choice of words, in essence the author is exactly right. Hope Pharmos management is taking notes. Here's the link: globes.co.il Best regards, Zvi

To: Ariella who wrote (1107)	8/10/1998 5:46:00 PM
From: arnie h	Read Replies (2) \| Respond to of 1491

Ariella: As usual, thanks for a fine summation on the outlook for PARS. It is indeed a positive one thanks to much good work by the company and its management. Yet, I wanted to note a number of aspects that give pause and will tend to restrain a steady upward trend in stock price. First, there are many low cost shares that will be coming into the fray over an extended period from conversion, warrants and options. These will be exerting downward pressure for the foreseeable future. Second, we have authorized almost 20 M shares over current projected levels. What will happen to those shares and why we were asked to go from 50 to 60 M isn't clear. Nor is it clear that we won't be asked for a further increase near term. Management seems to have a penchant for dilution. Third, there have been short sellers in PARS over quite a long period. Short sellers in stocks with prices in the $1-3 range are generally not a good omen. More to the point is the accuracy of that short selling. Whenever the shorts have increased, the price has dropped soon thereafter. While this has given us an opportunity to do a bit of trading, it opens some questions I'd prefer not to have. Fourth, managment has not yet articulated a long term vision and strategy for the company. At some point, this will be necessary. I'm just not sure what kind of a company Pharmos is. The strategy appears to be one of finding leads in Israel and then pursuing them opportunistically. This could wind up as a hodge podge, if we are not careful. Where we're going and how we're getting there needs attention. Regards, Arnie